Immunosuppressive drug-induced leukoencephalopathy in patients with liver transplant

European Journal of Gastroenterology and Hepatology

Volumn 10, Issue 5, 1998, Pages 433-436

  Idilman, Ramazan ^a,b   De Maria, Nicola ^a   Kugelmas, Marcelo ^a   Colantoni, Alessandra ^a   Van Thiel, D H ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Cyclosporin A; Immunosuppressive drugs; Leukoencephalopathy; Liver transplantation; Tacrolimus (FK506)

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; FEMALE; HEADACHE; HUMAN; LEUKOENCEPHALOPATHY; LIVER TRANSPLANTATION; MALE; NAUSEA; NEPHROTOXICITY; NEUROLOGICAL COMPLICATION; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SEIZURE;

EID: 0031798379     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199805000-00015     Document Type: Article

References (16)

1. Moreno E, Gomez SR, Gonzalez I, Loinaz C, Garcia I. Neurologic complications in liver transplantation. Acta Neurol Scand 1993; 87:25-31.
2. Lopez OL, Estol C, Colina I. Neurologic complications following liver transplantation. Hepatology 1992; 16:162-166.
3. Halloran PF. Molecular mechanisms of new immunosuppressants. Clin Transplant 1996; 10:118-123.
4. Shaw LM, Kaplan B, Kaufman D. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem 1996; 42:1316-1321.
5. Pratschke J, Neuhaus R, Tullius SG, Haller GW, Jonas S, Steinmueller T, et al. Treatment of cyclosporin-related adverse effects by conversion to tacrolimus after liver transplantation. Transplantation 1997; 64:938-940.
6. Shutter LA, Green JP, Newman NJ, Hooks MA, Gordon RD. Cortical blindness and white matter lesions in a patient receiving FK506 after liver transplantation. Neurology 1993; 43:2417-2418.
7. Small SL, Fukui MB, Bramblett GT, Eidelman BH. Immunosuppression-induced leukoencephalopathy from tacrolimus. Ann Neurol 1996; 40:575-580.
8. Hinchey J, Chaves C, Appignani B, Breen J, Pao L. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334:494-500.
9. Przepiorka D. Rational use of new immunosuppressive agents. In: Recent developments in transplantation medicine. Sollinger H (editor). Glenview, IL: Physicians and Scientists Publishing; 1994. pp. 1-8.
10. Fung JJ, Alessiani M, Abu-Elmagd K. Adverse effects associated with the use of FK506. Transplant Proc 1991; 23:3105-3108.
11. Freise CE, Rowley H, Lake J, Hebert M, Ascher NL. Similar clinical presentation of neurotoxicity following FK506 and cyclosporin in a liver transplant recipient. Transplant Proc 1991; 23:3173-3174.
12. Benigni A, Morigi M, Perico N. The acute effect of FK506 and cyclosporin on endothelial cell function and renal vascular resistance. Transplantation 1992; 54:775-780.
13. Igarashi T, Ishigatsubo Y, Ohno S. Central nervous system toxicity related to FK506 in patients with Behcet's disease. Ann Rheum Dis 1994; 53:350-351.
14. Sloane JP, Lwin KY, Gore M, Powles RL, Smith JF. Disturbance of blood-brain barrier after bone-marrow transplantation. Lancet 1985; 2:280-281.
15. Scherrer U, Vissing SF, Morgan BJ. Cyclosporin-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990; 323:693-699.
16. Johansson BB. The blood-brain barrier and cerebral blood flow in acute hypertension. Acta Med Scand 1983; 678 (suppl):107-112.